Poxel SA (FRA:7PO)
€ 0.166 -0.005 (-2.92%) Market Cap: 14.23 Mil Enterprise Value: 58.92 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 39/100

Poxel S.A. - Special Call Transcript

Dec 14, 2020 / 01:30PM GMT
Release Date Price: €6.56 (+3.63%)
Operator

Welcome to the Poxel KOL Investor Event Conference Call. My name is John, and I'll be your operator for today's call. (Operator Instructions)

And I will now turn the call over to Thomas Kuhn, CEO of Poxel. Thomas, you may begin.

Thomas Kuhn
Poxel S.A. - Co-Founder, CEO & Director

Thank you. Hello, everyone. Thank you for joining us today. And I'm Thomas Kuhn, the CEO of Poxel. And alongside me is David Moller, Executive Vice President and Chief Scientific Officer of Poxel.

The event today will feature presentations from Poxel and 2 NASH key opinion leaders: Dr. Kenneth Cusi, Chief of Division of Endocrinology, Diabetes and Metabolism in the Department of Medicine at the University of Florida; and Dr. Stephen Harrison, the Director of Summit Clinical Research. Thank you again, Ken and Stephen, for your -- for taking your precious time to be with us and to discuss our NASH pipeline.

The webcast today will cover detailed results from the Phase IIa STAMP-NAFLD study of PXL770 for the treatment of NASH, with a specific focus on the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot